Oncology Clinical Trials

Real‑World Evidence in Immunotherapy Research

Posted on digi By digi

Immuno‑oncology (IO) therapies such as PD‑1/PD‑L1 and CTLA‑4 inhibitors have reshaped cancer care, but traditional randomized trials can’t answer every question patients, payers, and regulators ask. Real‑world evidence (RWE)—clinical insights derived from routinely collected data like electronic health records (EHRs), cancer registries, and claims—helps fill gaps on effectiveness across diverse populations, long‑term safety, dosing schedules in practice, and treatment sequencing. For IO specifically, RWE is invaluable to characterize rare immune‑related adverse events (irAEs), assess outcomes beyond tightly controlled trial settings, and understand how biomarkers (e.g., PD‑L1 tiers, TMB) correlate with effectiveness in routine care.
Click to read the full article.

Immunotherapy Studies, Oncology Clinical Trials

Adaptive Design in Early Immuno‑Oncology Trials

Posted on digi By digi

Early‑phase immuno‑oncology (IO) trials face challenges that traditional cytotoxic programs don’t: delayed and atypical responses, non‑monotonic dose–toxicity and dose–efficacy relationships, and immune‑related adverse events (irAEs) that may emerge outside the classic 28‑day Dose‑Limiting Toxicity (DLT) window. Adaptive designs let teams adjust in real time—updating dose levels, cohort sizes, or enrolment eligibility as data accrue—without compromising trial integrity when pre‑specified in the protocol and Statistical Analysis Plan (SAP). In practice, adaptive IO trials shorten timelines to a biologically active dose, reduce exposure to subtherapeutic or unsafe doses, and enable smarter allocation to biomarker‑defined subgroups. They also align with modern regulatory expectations for learning‑confirming cycles and model‑informed drug development.
Click to read the full article.

Immunotherapy Studies, Oncology Clinical Trials

Genomic Alterations as Inclusion Criteria in Oncology Trials

Posted on digi By digi

Genomic inclusion criteria align the investigational therapy’s mechanism of action with patients most likely to benefit. Instead of enrolling “all‑comers,” you prospectively select participants with actionable alterations—EGFR exon 19 deletions, ALK/RET fusions, BRAF V600E, BRAFV600K, BRCA1/2 pathogenic variants, IDH1 R132H, NTRK fusions, and so on—so that the observed treatment effect reflects target engagement rather than chance. This approach increases biological signal, reduces sample size, and can support expedited pathways when effect sizes are large. That said, “genomics‑only” eligibility is not automatically optimal. In tumors with low alteration prevalence or uncertain predictive value, overly narrow criteria can cripple accrual, inflate screen‑fail rates, and introduce spectrum bias (you only study patients with extensive prior testing and access). A principled decision requires: (1) strong translational evidence that the alteration is predictive, not merely prognostic; (2) an analytical pipeline capable of reliably detecting the alteration; and (3) a trial design that preserves internal validity while remaining feasible across regions and labs.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Companion Diagnostics in Precision Oncology

Posted on digi By digi

Companion diagnostics (CDx) are in vitro diagnostic devices or imaging tools essential for the safe and effective use of a corresponding therapeutic product. In oncology, CDx testing is often the gateway to trial enrollment—patients must meet specific biomarker-defined eligibility criteria before receiving the investigational drug. For example, a HER2-targeted therapy requires HER2 amplification confirmation, an EGFR inhibitor needs exon 19 deletions or L858R mutations, and an ALK inhibitor demands ALK rearrangement detection.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Basket Trials Based on Genetic Markers

Posted on digi By digi

Basket trials represent a paradigm shift in oncology trial design. Instead of recruiting patients based solely on tumor histology (e.g., lung, breast, colorectal), basket trials enroll patients who share a common genetic alteration across multiple tumor types. For example, a trial may test a BRAF inhibitor in any solid tumor harboring a BRAF V600E mutation, regardless of whether it originated in the thyroid, lung, or colon.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Umbrella Trials Targeting Multiple Tumor Subtypes

Posted on digi By digi

Umbrella trials represent a master protocol design that evaluates multiple targeted therapies simultaneously within a single disease or tumor type. Unlike basket trials, which focus on one biomarker across different cancers, umbrella trials explore different biomarkers and targeted treatments in subgroups—or “sub-arms”—of the same cancer. This approach is particularly relevant in diseases like non-small cell lung cancer (NSCLC), where distinct genetic drivers (e.g., EGFR mutations, ALK rearrangements, ROS1 fusions, KRAS G12C) require different targeted agents.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Enrichment Strategies for Rare Mutations

Posted on digi By digi

Enrichment strategies in oncology clinical trials refer to the deliberate selection of a patient population most likely to benefit from a targeted therapy based on biomarker status. This is particularly critical for rare mutations, where the prevalence in the general population may be less than 1%. Without enrichment, screening large numbers of patients to find eligible participants can be prohibitively expensive and time-consuming.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Adaptive Enrichment Designs in Oncology Trials

Posted on digi By digi

Adaptive enrichment designs in oncology trials combine two powerful concepts: enrichment strategies that focus on biomarker-positive patients and adaptive trial features that allow protocol modifications based on interim results. This approach maximizes efficiency, particularly for rare biomarkers or heterogeneous patient populations, by dynamically refining eligibility criteria or treatment allocation as evidence accumulates.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Seamless Phase II/III Designs in Biomarker-Driven Oncology Trials

Posted on digi By digi

Seamless Phase II/III designs in oncology allow the trial to move from an early efficacy signal (Phase II) to confirmatory testing (Phase III) without pausing recruitment. This approach is particularly relevant for biomarker-driven trials, where patient identification can be challenging and interrupting recruitment could lead to loss of eligible participants.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials

Platform Trial Designs for Biomarker-Driven Oncology Studies

Posted on digi By digi

Platform trials represent a revolutionary approach to oncology drug development, particularly in biomarker-driven studies. Unlike traditional trials that focus on a single intervention, platform trials evaluate multiple treatments simultaneously under a single master protocol. This approach is highly efficient for biomarker-driven oncology, where patient populations may be small and highly stratified.
Click to read the full article.

Biomarker-Driven Trials, Oncology Clinical Trials